^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LYT-210

    i
    Other names: LYT-210
    Associations

    News

    Trials
    Company:
    PureTech
    Drug class:
    γδ TCR modulator, Gamma delta-1 T cell modulator
    Related drugs:
    Associations

    News

    Trials
    3years
    [VIRTUAL] Efficacy and characterization of a specific and potent monoclonal antibody, LYT-210, against immunosuppressive gd1 T cell in cancer (AACR 2021)
    We have developed a novel, therapeutic immuno-oncology strategy specifically targeting imunosuppressive γδ1cells. Our data support that this therapeutic approach may have the potential to be transformative for the treatment of cancers where γδ1T cells drive a pro-tumorigenic, immunosuppressive environment.
    Clinical
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    LYT-210